For more than 5 decades, @entity1229 has been the mainstay of therapy when oral anticoagulation is required. It has been shown to be effective in the prevention as well as treatment of various @entity1031 . However, drawbacks of @entity1229 , such as time-consuming requirements for frequent international normalized ratio monitoring, as well as drug and food interactions, have encouraged the development of alternative oral agents. One such agent, @entity3926 , has risen up to the challenge. Due to its predictable anticoagulation response, @entity3926 does not require routine anticoagulation monitoring. Another advantage @entity3926 has over @entity1229 is its more favorable drug and food interaction profiles. @entity3926 was shown to be noninferior to @entity1229 in studies evaluating the prevention of @entity64 and systemic @entity887 in @entity1 with @entity955 , thus leading to the US Food and Drug Administration approval for this indication. @entity3926 has also demonstrated efficacy in the prevention of @entity1211 in @entity1 undergoing total hip or knee replacement surgery as well as the prevention of recurrent @entity1211 , although these are not current Food and Drug Administration-approved indications. The safety profile appears to be similar to @entity1229 with regards to overall bleeding risk, though the risk for @entity360 was higher in @entity1 on @entity3926 150 mg twice daily. Disadvantages of @entity3926 may include a higher frequency of @entity2210 compared with @entity1229 , lack of dosing information in severe @entity8 , possible missed opportunities for periodic health examinations and interventions due to elimination of regular physician's visit for international normalized ratio monitoring, and drug costs. This article provides an overview of the clinical studies, pharmacokinetic profile, adverse effects, drug interactions as well as advantages and disadvantages associated with @entity3926 .

Dabigatran etexilate: the first oral anticoagulant available in the United States since XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['Dabigatran', 'dabigatran'] @entity887 :: ('MESH:D004617', 'Disease') :: ['embolism'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic disorders'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation'] @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism'] @entity360 :: ('MESH:D006471', 'Disease') :: ['gastrointestinal bleeds'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin']
@entity1229 :: (MESH:D014859,Chemical) :: ['warfarin']
